NEW GLP-1 ANALYSES

DE602019085528T2Active Publication Date: 2026-06-03SUN PHARMACEUTICAL INDUSTRIES LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
SUN PHARMACEUTICAL INDUSTRIES LTD
Filing Date
2019-04-05
Publication Date
2026-06-03

AI Technical Summary

Technical Problem

Existing GLP-1 analogs have short half-lives and require frequent administration, leading to suboptimal patient compliance and efficacy in treating diabetes and obesity.

Method used

Development of GLP-1 analogs with an additional Leu or Ile at the C-terminal, acylated with protracting moieties to enhance stability and duration of action, suitable for oral administration.

Benefits of technology

The acylated GLP-1 analogs exhibit improved potency and prolonged duration of action, reducing blood glucose levels and body weight effectively, as demonstrated in animal models.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.